WO2017192991A1 - Selective estrogen receptor down-regulators (serds) - Google Patents
Selective estrogen receptor down-regulators (serds) Download PDFInfo
- Publication number
- WO2017192991A1 WO2017192991A1 PCT/US2017/031297 US2017031297W WO2017192991A1 WO 2017192991 A1 WO2017192991 A1 WO 2017192991A1 US 2017031297 W US2017031297 W US 2017031297W WO 2017192991 A1 WO2017192991 A1 WO 2017192991A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituent
- serd
- compound
- formula
- salt
- Prior art date
Links
- 229940119564 Selective estrogen receptor downregulator Drugs 0.000 title abstract description 36
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 15
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 230000002062 proliferating effect Effects 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 52
- 229910052796 boron Inorganic materials 0.000 claims description 34
- 239000012453 solvate Substances 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 102000015694 estrogen receptors Human genes 0.000 claims description 8
- 108010038795 estrogen receptors Proteins 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 2
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 abstract description 16
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 13
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 229940125944 selective estrogen receptor degrader Drugs 0.000 description 93
- 125000001424 substituent group Chemical group 0.000 description 17
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 15
- 229960002258 fulvestrant Drugs 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 230000002194 synthesizing effect Effects 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 6
- 229960001603 tamoxifen Drugs 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000003886 aromatase inhibitor Substances 0.000 description 5
- 229940046844 aromatase inhibitors Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000009261 endocrine therapy Methods 0.000 description 5
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 102100038595 Estrogen receptor Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- BURHGPHDEVGCEZ-KJGLQBJMSA-N (e)-3-[4-[(e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-enyl]phenyl]prop-2-enoic acid Chemical compound C=1C=C(F)C=C(Cl)C=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(O)=O)C=C1 BURHGPHDEVGCEZ-KJGLQBJMSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940087861 faslodex Drugs 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- DFBDRVGWBHBJNR-BBNFHIFMSA-N (e)-3-[3,5-difluoro-4-[(1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H](N2CC(C)(C)F)C)=C(F)C=C(\C=C\C(O)=O)C=C1F DFBDRVGWBHBJNR-BBNFHIFMSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CSBHVAYSNJPBIF-PXNRCKDYSA-N CC/C(/c1ccccc1)=C(/c1ccc(B2OC(C)(C)C(C)(C)O2)cc1)\c1ccc(/C=C/C(O)=O)cc1 Chemical compound CC/C(/c1ccccc1)=C(/c1ccc(B2OC(C)(C)C(C)(C)O2)cc1)\c1ccc(/C=C/C(O)=O)cc1 CSBHVAYSNJPBIF-PXNRCKDYSA-N 0.000 description 1
- ZVZKRBCUMJXZMF-NLUKHSSPSA-N CC1(C)OB(c2cc(-c3cc(/C=C/C(O)=O)cc(F)c3[C@H](C3)C4[C@@H](CC5)[C@H](CC6)[C@@]3(C)[C@H]6O)c4c5c2)OC1(C)C Chemical compound CC1(C)OB(c2cc(-c3cc(/C=C/C(O)=O)cc(F)c3[C@H](C3)C4[C@@H](CC5)[C@H](CC6)[C@@]3(C)[C@H]6O)c4c5c2)OC1(C)C ZVZKRBCUMJXZMF-NLUKHSSPSA-N 0.000 description 1
- RUJGFPHHYQRYIZ-NTEUORMPSA-N CC1(C)OB(c2ccc(C(Cc3ccc(/C=C/C(O)=O)cc3)=C(c(cc3Cl)ccc3F)C(O3)=O)c3c2)OC1(C)C Chemical compound CC1(C)OB(c2ccc(C(Cc3ccc(/C=C/C(O)=O)cc3)=C(c(cc3Cl)ccc3F)C(O3)=O)c3c2)OC1(C)C RUJGFPHHYQRYIZ-NTEUORMPSA-N 0.000 description 1
- 0 CCC(c1c(*)cc(*)cc1)=C([C@@]1C(*)=CC(C=CC(O)=O)=CC1*)c1ccc(*)cc1 Chemical compound CCC(c1c(*)cc(*)cc1)=C([C@@]1C(*)=CC(C=CC(O)=O)=CC1*)c1ccc(*)cc1 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000007519 polyprotic acids Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
- C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
- C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
Definitions
- the present disclosure relates to orally bioavailable selective estrogen receptor down- regulators (SERDs), and methods for making the same.
- the disclosure also relates to pharmaceutical compositions comprising these SERDs, and methods for using the same for treatment of estrogen receptor mediated pathological developments, including cancers.
- the SERDs described here can provide effective endocrine therapy for breast cancers, especially those that express estrogen receptor (estrogen receptor positive or "ER+” breast cancers), as the first line adjuvant treatment regimen, or in the second-line setting as treatment for patients with disease progression after prior endocrine therapy such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs).
- SERMs selective estrogen receptor modulators
- AIs aromatase inhibitors
- SERM tamoxifen
- raloxifene toremifene
- AIs aromatase inhibitors
- SERD fullvestrant
- Tamoxifen is a first-line agent for pre -menopausal patients and for women requiring secondary chemoprevention after a DCIS diagnosis.
- AIs are generally preferred to tamoxifen because of more favorable time to progression and less severe side effects [4, 5] .
- fulvestrant has proven to be a very effective SERD, and is currently the only FDA approved therapy for breast cancer progressing after SERM or AI treatments [6, 7].
- fulvestrant has very poor bioavailability if administered orally, thus its standard route of administration is intramuscular (i.m.) injection, which takes 3-4 months to reach steady state serum concentration and has negatively impacted its widespread use [8].
- the SERDs of the present disclosure are compounds of the formula (I):
- R 3 substituent point of attachment is on the substituent boron atom of R 3
- R 4 substituent point of attachment is on the substituent boron atom of R 4
- FIG. 1 An example of a SERD of Formula (I) is SERD 1, and the general synthetic scheme for synthesizing SERDs of Formula (I) is shown in FIG. 1.
- the SERDs of the present disclosure are compounds of the formula (II): Formula (II)
- X O, S, NH, OCH 2 , SCH 2 , NHCH 2 , CH 2 0, CH 2 S, or CH 2 NH 2
- R 3 substituent point of attachment is on the substituent boron atom of R 3
- R 4 substituent point of attachment is on the substituent boron atom of R 4
- FIG. 2 An example of a SERD of Formula ( ⁇ ) is SERD 2
- the general synthetic scheme for synthesizing SERDs of Formula (IT) is shown in FIG. 2.
- the SERDs of the present disclosure are compounds of the formula (III):
- SERD 3 substituent point of attachment is on the substituent boron atom of R 3
- R 4 substituent point of attachment is on the substituent boron atom of R 4
- FIG. 3 An example of a SERD of Formula (III) is SERD 3
- the general synthetic scheme for synthesizing SERDs of Formula (III) is shown in FIG. 3.
- the SERDs of the present disclosure are compounds of the formula (IV):
- R 1 H, OH, OMe, Me, CI, F, or CF 3 ;
- R 2 H, OH, OMe, Me, CI, F, or CF 3 ;
- R 4 H, F, or CI
- R 5 H, F, or CI
- R 3 substituent point of attachment is on the substituent boron atom of R3, as depicted more fully by the example SERD structures provided below.
- An example of a SERD of Formula (IV) is SERD 4, and the general synthetic scheme for synthesizing SERDs of Formula (IV) is shown in FIG. 4.
- the SERDs of the present disclosure are compounds of the formula (V):
- R 1 H, OH, OMe, Me, CI, F, or CF 3 ;
- R 2 H, OH, OMe, Me, CI, F, or CF 3 ;
- R 4 H, F, or CI
- R 5 H, F, or CI
- R 3 substituent point of attachment is on the substituent boron atom of R 3 , as depicted more fully by the example SERD structures provided below.
- An example of a SERD of Formula (V) is SERD 5, and the general synthetic scheme for synthesizing SERDs of Formula (V) is shown in FIG. 5.
- the SERDs of the present disclosure are compounds of the formula (VI):
- R 1 H, OH, OMe, Me, CI, F, or CF 3 ;
- R 2 H, OH, OMe, Me, CI, F, or CF 3 ;
- R 4 H, F, or CI
- R 3 substituent point of attachment is on the substituent boron atom of R 3 , as depicted more fully by the example SERD structures provided below.
- An example of a SERD of Formula (VI) is SERD 6, and the general synthetic scheme for synthesizing SERDs of Formula (VI) is shown in FIG. 6.
- the SERDs of the present disclosure are compounds of the formula (VII):
- R H, OH, OMe
- R 1 substituent point of attachment is on the substituent boron atom of R 1
- R 2 substituent point of attachment is on the substituent boron atom of R 2
- FIG. 7 An example of a SERD of Formula (VII) is SERD 7, and the general synthetic scheme for synthesizing SERDs of Formula (VII) is shown in FIG. 7.
- the SERDs of the present disclosure are compounds of the formula (VIII):
- R 1 substituent point of attachment is on the substituent boron atom of R 1
- R 2 substituent point of attachment is on the substituent boron atom of R 2
- FIG. 8 An example of a SERD of Formula (VIII) is SERD 8
- the general synthetic scheme for synthesizing SERDs of Formula (VIII) is shown in FIG. 8.
- the SERDs of the present disclosure are compounds of the formula (IX):
- R 2 substituent point of attachment is on the substituent boron atom of R 2
- R 3 substituent point of attachment is on the substituent boron atom of R 3 , as depicted more fully by the example SERD structures provided below.
- An example of a SERD of Formula (IX) is SERD 9, and the general synthetic scheme for synthesizing SERDs of Formula (IX) is shown in FIG. 9.
- the SERDs of the present disclosure are compounds of the formula (X): wherein the R 1 substituent point of attachment is on the substituent boron atom of R 1 , and the R 2 substituent point of attachment is on the substituent boron atom of R 2 , as depicted more fully by the example SERD structures provided below.
- An example of a SERD of Formula (X) is SERD 10, and the general synthetic scheme for synthesizing SERDs of Formula (X) is shown in FIG. 10.
- the SERD is a compound of formula ( ⁇ ) having the following structure, and denoted SERD 1 ⁇ see also FIG. 1):
- the oral SERD is a compound of formula (II) having the following structure, and denoted SERD 2 ⁇ see also FIG. 2) :
- the oral SERD is a compound of formula (III) having the following structure, and denoted SERD 3 ⁇ see also FIG. 3) :
- the oral SERD is a compound of formula (IV) having the following structure, and denoted SERD 4 ⁇ see also FIG. 4) :
- the oral SERD is a compound of formula (V) having the following structure, and denoted SERD 5 ⁇ see also FIG. 5) :
- the oral SERD is a compound of formula (VI) having the following structure, and denoted SERD 6 ⁇ see also FIG. 6) :
- the oral SERD is a compound of formula (VII) having the following structure, and denoted SERD 7 ⁇ see also FIG. 7) :
- the oral SERD is a compound of formula (VIII) having the following structure, and denoted SERD 8 ⁇ see also FIG. 8) :
- the oral SERD is a compound of formula (X) having the following structure, and denoted SERD 10 (see also FIG. 10) :
- the disclosure provides for a pharmaceutical composition in the form of at least one SERD for treatment of proliferative diseases, including cancer, and in particular breast cancer, that can obtain clinical benefits from SERD therapy.
- the composition may comprise at least one SERD in an amount that is therapeutically effective.
- the disclosure therefore relates to use of a SERD according to any one of Formulas I through X, or combinations thereof, for treatment and prevention of proliferative diseases— including cancer— that can derive clinical benefits from such use.
- compositions of the present disclosure can be in any form known to those of skill in the art.
- the pharmaceutical compositions are in a form of a product for oral delivery, said product form being selected from a group consisting of a concentrate, dried powder, liquid, capsule, pellet, and pill.
- the pharmaceutical compositions of the disclosure are in the form of a product for parenteral administration including intravenous, intradermal, intramuscular, and subcutaneous administration.
- the pharmaceutical compositions disclosed herein may also further comprise carriers, binders, diluents, and excipients.
- the present disclosure relates to new SERD compounds and their pharmaceutically acceptable salts; pharmaceutical compositions comprising the new SERD compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new SERD compounds, either alone or in combination with at least one additional therapeutic agent, in the treatment of proliferative diseases including breast cancer at any stage of the disease diagnosis.
- the combination with an additional therapeutic agent may take the form of combining the new SERD compounds with any known therapeutic agent.
- Salts of the compounds according to the disclosure include all inorganic and organic salts, especially all pharmaceutically acceptable inorganic and organic salts, particularly all pharmaceutically acceptable inorganic and organic salts customarily used in pharmacy.
- salts of the compounds according to the disclosure including all inorganic and organic salts, especially all pharmaceutically acceptable inorganic and organic salts, particularly all pharmaceutically acceptable inorganic and organic salts customarily used in pharmacy.
- salts include, but are not limited to, lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, meglumine, ammonium, salts optionally derived from NH 3 or organic amines having from 1 to 16 C-atoms such as, e.g., ethylamine, diethylamine, triethylamine,
- ethyldiisopropylamine monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylendiamine, N-methylpiperindine and guanidinium salts.
- the salts include water-insoluble and, particularly, water-soluble salts.
- the compounds of formulas ( ⁇ ) through (X) according to this disclosure as well as their salts may contain, e.g., when isolated in crystalline form, varying amounts of solvents. Included within the scope of the disclosure are therefore all solvates and in particular all hydrates of the compounds of formulas ( ⁇ ) through (X) according to this disclosure as well as all solvates and in particular all hydrates of the salts of the compounds of formulas ( ⁇ ) through (X) according to this disclosure.
- the compounds of the disclosure may, depending on their structure, exist in different stereoisomeric forms. These forms include configurational isomers or optically conformational isomers (enantiomers and/or diastereoisomers including those of atropisomers) .
- the present disclosure therefore includes enantiomers, diastereoisomers as well as mixtures thereof. From those mixtures of enantiomers and/or disastereoisomers pure stereoisomeric forms can be isolated with methods known in the art, preferably methods of chromatography, especially high pressure liquid chromatography (HPLC) using achiral or chiral phase.
- HPLC high pressure liquid chromatography
- the disclosure further includes all mixtures of the stereoisomers mentioned above independent of the ratio, including the racemates.
- the compounds of the disclosure may, depending on their structure, exist in various stable isotopic forms. These forms include those in which one or more hydrogen atoms have been replaced with deuterium atoms, those in which one or more nitrogen atoms have been replaced with 15 N atoms, or those in which one or more atoms of carbon, fluorine, chlorine, bromine, sulfur, or oxygen have been replaced by the stable isotope of the respective, original atoms.
- Another object of the disclosure is to provide a composition, for example a pharmaceutical composition, comprising at least one SERD compound in an amount effective for the indication of proliferative diseases such as cancer, including but not limited to endocrine related cancer, for treatment and prevention of recurrence.
- a kit comprising a composition containing at least one SERD for treatment and prevention of cancer and cancer related morbidities.
- the composition of the kit may comprise at least one carrier, at least one binder, at least one diluent, at least one excipient, at least one other therapeutic agent, or mixtures thereof.
- the methods for treating a clinical indication by the SERD compounds disclosed herein may be effectuated by administering a therapeutically effective amount of the SERD to a patient in need thereof, this therapeutically effective amount may comprise administration of the prodrug to the patient at 1 mg/kg/ day, 2 mg/kg/ day, 3 mg/kg/ day, 4 mg/kg/ day, 5 mg/kg/ day, 10 mg/kg/ day and 20 mg/kg/ day.
- amounts ranging from about 0.001mg/kg/ day to about 0.01 mg/kg/ day, or about 0.01 mg/kg/ day to about 0.1 mg/kg/ day, or about 0.1 mg/kg/ day to about 1 mg/kg/ day, or about 1 mg/kg/ day to 10 mg/kg/ day, or about 10 mg/kg/ day to about 100 mg/kg/ day are also contemplated.
- the at least one SERD compound has a purity of ⁇ 75%, ⁇ 80%, ⁇ 85%, > 90%, > 95%, > 96%, > 97%, or > 98%, and preferably > 99%.
- One aspect of the present disclosure is the compounds disclosed herein as well as the intermediates as used for their synthesis.
- FIG. 1 shows the £ general synthetic scheme for preparation of SERD 1.
- FIG.2 shows the g eneral synthetic scheme for preparation of SERD 2.
- FIG. 3 shows the £ general synthetic scheme for preparation of SERD 3.
- FIG. 4 shows the £ general synthetic scheme for preparation of SERD 4.
- FIG. 5 shows the £ general synthetic scheme for preparation of SERD 5.
- FIG. 6 shows the £ general synthetic scheme for preparation of SERD 6.
- FIG. 7 shows the £ general synthetic scheme for preparation of SERD 7.
- FIG. 8 shows the £ general synthetic scheme for preparation of SERD 8.
- FIG. 9 shows the £ general synthetic scheme for preparation of SERD 9.
- FIG. 10 shows the general synthetic scheme for preparation of SERD 10.
- FIG. 11 shows the antiestrogenic effects of representative SERDs in T47D- Bluc cells.
- FIG. 12 shows the effects of representative SERDs in MCF-7 E3 proliferation assay.
- FIG. 13 shows the effect of SERD 4 on estrogen receptor a (ERa) expression.
- Western blots showing ER protein expression in MCF-7 cells dramatically downregulated by GDC-810, SERD4, and GW-7604, respectively, in a dose-dependent manner.
- FIG. 14 shows the effect of SERD 9 on estrogen receptor a (ERa) expression.
- FIG. 15 shows the binding of SERD 4 and SERD 9 to estrogen receptor a (ERa) with high affinity.
- FIG. 16 shows the oral bioavailability of SERD 4 and GW7604 in rats after a single dose of 10 mg/kg per os (p.o.) .
- FIG. 17 shows the oral bioavailability of SERD 9 in mice after a single dose of 5 mg/kg p.o.
- FIG. 18 shows the efficacy of SERD 9 in mice bearing breast tumor xenograft when orally administered at two doses, as compared to that of fulvestrant administered by subcutaneous injection.
- minimize or “reduce”, or derivatives thereof, include a complete or partial inhibition of a specified biological effect (which is apparent from the context in which the terms “minimize” or “reduce” are used).
- Table 1 below shows the cytotoxicity of the representative SERDs in various breast cancer cell lines.
- the compounds according to the disclosure are isolated and purified in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as chromatography on a suitable support material.
- reverse phase preparative HPLC of compounds of the present disclosure which possess a sufficiently basic or acidic functionality may result in the formation of a salt, such as, in the case of a compound of the present disclosure which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present disclosure which is sufficiently acidic, an ammonium salt for example.
- Salts of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays. Additionally, the drying process during the isolation of compounds of the present disclosure may not fully remove traces of cosolvents, especially such as formic acid or trifluoroacetic acid, to give solvates or inclusion complexes. The person skilled in the art will recognize which solvates or inclusion complexes are acceptable to be used in subsequent biological assays.
- Salts of the compounds of formulas ( ⁇ ) through (X) according to the disclosure can be obtained by dissolving the free compound in a suitable solvent (for example a ketone such as acetone, methylethylketone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as methanol, ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added.
- a suitable solvent for example a ketone such as acetone, methylethylketone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight
- Robertson JF. Fulvestrant (Faslodex)— how to make a good drug better. Oncologist. 2007 Jul; 12(7):774-84.
- NCT01823835 A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer, 2013, http:/ clinicaltrials.gov NCT02248090, AZD9496 First Time in Patients Ascending Dose Study, 2014,
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The present disclosure relates to orally bioavailable selective estrogen receptor down-regulators (SERDs) and the synthesis of the same. Further, the present disclosure teaches the utilization of the orally bioavailable selective estrogen receptor down-regulators (SERDs) in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ breast cancer.
Description
SELECTIVE ESTROGEN RECEPTOR DOWN-REGULATORS (SERDS)
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This international application claims the benefit of U.S. Provisional Patent Application No. 62/332,541, filed on 6 May 2016, which is hereby incorporated by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention was made with government support under grant number 5G12MD007595 awarded by the National Institute on Minority Health and Health Disparities (NIMHD) . The government has certain rights in the invention.
BACKGROUND
1. Field
[0003] The present disclosure relates to orally bioavailable selective estrogen receptor down- regulators (SERDs), and methods for making the same. The disclosure also relates to pharmaceutical compositions comprising these SERDs, and methods for using the same for treatment of estrogen receptor mediated pathological developments, including cancers.
[0004] The SERDs described here can provide effective endocrine therapy for breast cancers, especially those that express estrogen receptor (estrogen receptor positive or "ER+" breast cancers), as the first line adjuvant treatment regimen, or in the second-line setting as treatment for patients with disease progression after prior endocrine therapy such as selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs).
2. Description of Related Art
[0005] Breast cancer remains the most common cancer in women worldwide, with over 1.7 million new cases diagnosed in 2012 (second most common cancer overall). This represents about 12% of all new cancer cases and 25% of all cancers in women. Nearly 80% of breast cancer cases are estrogen receptor positive (ER+) [1, 2] and for most of these patients, endocrine therapy is an appropriate option in both the adjuvant and advanced setting. Current endocrine therapy for ER+ breast cancer comprises three regimen options that can be used in varied sequences for optimal outcome: SERM {e.g., tamoxifen, raloxifene, toremifene), aromatase inhibitors (AIs, including anastrozole, exemestane, letrozole), and SERD (fulvestrant) [3] . Tamoxifen is a first-line agent for pre -menopausal patients and for women
requiring secondary chemoprevention after a DCIS diagnosis. In postmenopausal women AIs are generally preferred to tamoxifen because of more favorable time to progression and less severe side effects [4, 5] . However, most patients with advanced metastatic breast cancer eventually develop resistance to tamoxifen or AI treatment while retaining the expression of ERa in the recurrent and/or progressive disease. This clinical information provides a viable therapeutic rationale for using fulvestrant to which most of the AI- or tamoxifen-resistant breast cancers are not cross-resistant. Indeed, fulvestrant has proven to be a very effective SERD, and is currently the only FDA approved therapy for breast cancer progressing after SERM or AI treatments [6, 7]. Unfortunately, fulvestrant has very poor bioavailability if administered orally, thus its standard route of administration is intramuscular (i.m.) injection, which takes 3-4 months to reach steady state serum concentration and has negatively impacted its widespread use [8]. Moreover, even at a recently approved higher dose of 500mg, the peak blood concentration of fulvestrant remains below a modest 25 ng/ mL in the FINDER1 and FINDER2 clinical trials [9, 10], suggesting that its optimal efficacy in patients may not have been achieved [7]. In addition, it still takes 1 month to reach steady state fulvestrant concentration in patient plasma [7] . The promising clinical utility of fulvestrant and the increasing understanding of its mechanism of action have motivated the development of SERDs with greater bioavailability and efficacy [11, 12]. Thus, a need for SERDs with at least improved bioavailability remains.
BRIEF SUMMARY
[0006] In an embodiment, the SERDs of the present disclosure are compounds of the formula (I):
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, and the R4 substituent point of attachment is on the substituent boron atom of R4, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (I) is SERD 1, and the general synthetic scheme for synthesizing SERDs of Formula (I) is shown in FIG. 1.
[0007] In another embodiment, the SERDs of the present disclosure are compounds of the formula (II):
Formula (II)
wherein
X = O, S, NH, OCH2, SCH2, NHCH2, CH20, CH2S, or CH2NH2
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, and the R4 substituent point of attachment is on the substituent boron atom of R4, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (ΙΓ) is SERD 2, and the general synthetic scheme for synthesizing SERDs of Formula (IT) is shown in FIG. 2.
- A -
[0008] In another embodiment, the SERDs of the present disclosure are compounds of the formula (III):
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, and the R4 substituent point of attachment is on the substituent boron atom of R4, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (III) is SERD 3, and the general synthetic scheme for synthesizing SERDs of Formula (III) is shown in FIG. 3.
[0009] In another embodiment, the SERDs of the present disclosure are compounds of the formula (IV):
Formula (IV)
wherein
R1 = H, OH, OMe, Me, CI, F, or CF3;
R2 = H, OH, OMe, Me, CI, F, or CF3;
R4 = H, F, or CI;
R5 = H, F, or CI; and
R3 =
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (IV) is SERD 4, and the general synthetic scheme for synthesizing SERDs of Formula (IV) is shown in FIG. 4.
[0010] In another embodiment, the SERDs of the present disclosure are compounds of the formula (V):
Formula (V)
wherein
R1 = H, OH, OMe, Me, CI, F, or CF3;
R2 = H, OH, OMe, Me, CI, F, or CF3;
R4 = H, F, or CI;
R5 = H, F, or CI; and
R3 =
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (V) is SERD 5, and the general synthetic scheme for synthesizing SERDs of Formula (V) is shown in FIG. 5.
[0011] In another embodiment, the SERDs of the present disclosure are compounds of the formula (VI):
wherein
R1 = H, OH, OMe, Me, CI, F, or CF3;
R2 = H, OH, OMe, Me, CI, F, or CF3;
R4 = H, F, or CI;
R5 = H, F, or CI; and
R3 =
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (VI) is SERD 6, and the general synthetic scheme for synthesizing SERDs of Formula (VI) is shown in FIG. 6.
[0012] In another embodiment, the SERDs of the present disclosure are compounds of the formula (VII):
II)
wherein
R = H, OH, OMe,
R2
wherein the R1 substituent point of attachment is on the substituent boron atom of R1, and the R2 substituent point of attachment is on the substituent boron atom of R2, as depicted more fully by the
example SERD structures provided below. An example of a SERD of Formula (VII) is SERD 7, and the general synthetic scheme for synthesizing SERDs of Formula (VII) is shown in FIG. 7.
[0013] In another embodiment, the SERDs of the present disclosure are compounds of the formula (VIII):
wherein the R1 substituent point of attachment is on the substituent boron atom of R1, and the R2 substituent point of attachment is on the substituent boron atom of R2, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (VIII) is SERD 8, and the general synthetic scheme for synthesizing SERDs of Formula (VIII) is shown in FIG. 8.
[0014] In another embodiment, the SERDs of the present disclosure are compounds of the formula (IX):
wherein the R2 substituent point of attachment is on the substituent boron atom of R2, and the R3 substituent point of attachment is on the substituent boron atom of R3, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (IX) is SERD 9, and the general synthetic scheme for synthesizing SERDs of Formula (IX) is shown in FIG. 9.
[0015] In another embodiment, the SERDs of the present disclosure are compounds of the formula (X):
wherein the R1 substituent point of attachment is on the substituent boron atom of R1, and the R2 substituent point of attachment is on the substituent boron atom of R2, as depicted more fully by the example SERD structures provided below. An example of a SERD of Formula (X) is SERD 10, and the general synthetic scheme for synthesizing SERDs of Formula (X) is shown in FIG. 10.
[0016] In a preferred embodiment, the SERD is a compound of formula (ΐ) having the following structure, and denoted SERD 1 {see also FIG. 1):
SERD 1
[0017] In a preferred embodiment, the oral SERD is a compound of formula (II) having the following structure, and denoted SERD 2 {see also FIG. 2) :
SERD 2
[0018] In a preferred embodiment, the oral SERD is a compound of formula (III) having the following structure, and denoted SERD 3 {see also FIG. 3) :
SERD 3
[0019] In a preferred embodiment, the oral SERD is a compound of formula (IV) having the following structure, and denoted SERD 4 {see also FIG. 4) :
SERD 4
[0020] In a preferred embodiment, the oral SERD is a compound of formula (V) having the following structure, and denoted SERD 5 {see also FIG. 5) :
SERD 5
[0021] In a preferred embodiment, the oral SERD is a compound of formula (VI) having the following structure, and denoted SERD 6 {see also FIG. 6) :
SERD 6
[0022 ] In a preferred embodiment, the oral SERD is a compound of formula (VII) having the following structure, and denoted SERD 7 {see also FIG. 7) :
SERD 7
[0023] In a preferred embodiment, the oral SERD is a compound of formula (VIII) having the following structure, and denoted SERD 8 {see also FIG. 8) :
SERD 9
[0025] In a preferred embodiment, the oral SERD is a compound of formula (X) having the following structure, and denoted SERD 10 (see also FIG. 10) :
SERD 10
[0026] In an embodiment, the disclosure provides for a pharmaceutical composition in the form of at least one SERD for treatment of proliferative diseases, including cancer, and in particular breast cancer, that can obtain clinical benefits from SERD therapy. The composition may comprise at least one SERD in an amount that is therapeutically effective.
[0027] The disclosure therefore relates to use of a SERD according to any one of Formulas I through X, or combinations thereof, for treatment and prevention of proliferative diseases— including cancer— that can derive clinical benefits from such use.
[0028] The pharmaceutical compositions of the present disclosure can be in any form known to those of skill in the art. For instance, in some embodiments the pharmaceutical compositions are in a form of a product for oral delivery, said product form being selected from a group consisting of a concentrate, dried powder, liquid, capsule, pellet, and pill. In other embodiments, the pharmaceutical compositions of the disclosure are in the form of a product for parenteral administration including intravenous, intradermal, intramuscular, and subcutaneous administration. The pharmaceutical compositions disclosed herein may also further comprise carriers, binders, diluents, and excipients.
[0029] Also, in other aspects, the present disclosure relates to new SERD compounds and their pharmaceutically acceptable salts; pharmaceutical compositions comprising the new SERD compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new SERD compounds, either alone or in combination with at least one additional therapeutic agent, in the treatment of proliferative diseases including breast cancer at any stage of the disease diagnosis. The combination with an additional therapeutic agent may take the form of combining the new SERD compounds with any known therapeutic agent.
[0030] Salts of the compounds according to the disclosure include all inorganic and organic salts, especially all pharmaceutically acceptable inorganic and organic salts, particularly all pharmaceutically acceptable inorganic and organic salts customarily used in pharmacy.
[0031] One aspect of the disclosure is salts of the compounds according to the disclosure including all inorganic and organic salts, especially all pharmaceutically acceptable inorganic and organic salts, particularly all pharmaceutically acceptable inorganic and organic salts customarily used in pharmacy.
[0032 ] Examples of salts include, but are not limited to, lithium, sodium, potassium, calcium, aluminum, magnesium, titanium, meglumine, ammonium, salts optionally derived from NH3 or organic amines having from 1 to 16 C-atoms such as, e.g., ethylamine, diethylamine, triethylamine,
ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylendiamine, N-methylpiperindine and guanidinium salts.
[0033] The salts include water-insoluble and, particularly, water-soluble salts.
[0034] According to the person skilled in the art the compounds of formulas (Γ) through (X) according to this disclosure as well as their salts may contain, e.g., when isolated in crystalline form, varying amounts of solvents. Included within the scope of the disclosure are therefore all solvates and in particular all hydrates of the compounds of formulas (Γ) through (X) according to this disclosure as well as all solvates and in particular all hydrates of the salts of the compounds of formulas (Γ) through (X) according to this disclosure.
[0035] The compounds according to the disclosure and their salts can exist in the form of tautomers which are included in the embodiments of the disclosure.
[0036] The compounds of the disclosure may, depending on their structure, exist in different stereoisomeric forms. These forms include configurational isomers or optically conformational isomers (enantiomers and/or diastereoisomers including those of atropisomers) . The present disclosure therefore includes enantiomers, diastereoisomers as well as mixtures thereof. From those mixtures of enantiomers and/or disastereoisomers pure stereoisomeric forms can be isolated with methods known in the art, preferably methods of chromatography, especially high pressure liquid chromatography (HPLC) using achiral or chiral phase. The disclosure further includes all mixtures of the stereoisomers mentioned above independent of the ratio, including the racemates.
[0037] The compounds of the disclosure may, depending on their structure, exist in various stable isotopic forms. These forms include those in which one or more hydrogen atoms have been replaced with deuterium atoms, those in which one or more nitrogen atoms have been replaced with 15N atoms, or those in which one or more atoms of carbon, fluorine, chlorine, bromine, sulfur, or oxygen have been replaced by the stable isotope of the respective, original atoms.
[0038] Some of the compounds and salts according to the disclosure may exist in different crystalline forms (polymorphs) which are within the scope of the disclosure.
[0039] It is a further object of the disclosure to provide SERD compounds, methods of synthesizing the SERD compounds, methods of manufacturing the SERD compounds, and methods of using the SERD compounds.
[0040] Another object of the disclosure is to provide a composition, for example a pharmaceutical composition, comprising at least one SERD compound in an amount effective for the indication of proliferative diseases such as cancer, including but not limited to endocrine related cancer, for treatment and prevention of recurrence.
[0041] A further object of the disclosure is a kit, comprising a composition containing at least one SERD for treatment and prevention of cancer and cancer related morbidities. The composition of the kit may comprise at least one carrier, at least one binder, at least one diluent, at least one excipient, at least one other therapeutic agent, or mixtures thereof.
[0042] The methods for treating a clinical indication by the SERD compounds disclosed herein, may be effectuated by administering a therapeutically effective amount of the SERD to a patient in need thereof, this therapeutically effective amount may comprise administration of the prodrug to the patient at 1 mg/kg/ day, 2 mg/kg/ day, 3 mg/kg/ day, 4 mg/kg/ day, 5 mg/kg/ day, 10 mg/kg/ day and 20 mg/kg/ day. Alternatively, amounts ranging from about 0.001mg/kg/ day to about 0.01 mg/kg/ day, or about 0.01 mg/kg/ day to about 0.1 mg/kg/ day, or about 0.1 mg/kg/ day to about 1 mg/kg/ day, or about 1 mg/kg/ day to 10 mg/kg/ day, or about 10 mg/kg/ day to about 100 mg/kg/ day are also contemplated.
[0043] In certain aspects, the at least one SERD compound has a purity of≥ 75%,≥ 80%,≥ 85%, > 90%, > 95%, > 96%, > 97%, or > 98%, and preferably > 99%.
[0044] One aspect of the present disclosure is the compounds disclosed herein as well as the intermediates as used for their synthesis.
[0045] While certain features of this invention shown and described below are pointed out in the annexed claims, the invention is not intended to be limited to the details specified, since a person of ordinary skill in the relevant art will understand that various omissions, modifications, substitutions, and changes in the forms and details of the invention illustrated and in its operation may be made without departing in any way from the spirit of the present invention. No feature of the invention is critical or essential unless it is expressly stated as being "critical" or "essential."
[0046] These and other features, aspects, and advantages of embodiments of the present disclosure will become better understood with regard to the following descriptions, claims, and accompanying drawings explained below.
BRIEF DESCRIPTION OF THE DRAWINGS
[0047] For a further understanding of the nature, objects, and advantages of the present disclosure, reference should be had to the following detailed description, read in conjunction with the following drawings, wherein like reference numerals denote like elements.
[0048] FIG. 1 shows the £ general synthetic scheme for preparation of SERD 1.
[0049] FIG.2 : shows the g eneral synthetic scheme for preparation of SERD 2.
[0050] FIG. 3 shows the £ general synthetic scheme for preparation of SERD 3.
[0051] FIG. 4 shows the £ general synthetic scheme for preparation of SERD 4.
[0052 ] FIG. 5 shows the £ general synthetic scheme for preparation of SERD 5.
[0053] FIG. 6 shows the £ general synthetic scheme for preparation of SERD 6.
[0054] FIG. 7 shows the £ general synthetic scheme for preparation of SERD 7.
[0055] FIG. 8 shows the £ general synthetic scheme for preparation of SERD 8.
[0056] FIG. 9 shows the £ general synthetic scheme for preparation of SERD 9.
[0057] FIG. 10 shows the general synthetic scheme for preparation of SERD 10.
[0058] FIG. 11 shows the antiestrogenic effects of representative SERDs in T47D- Bluc cells.
[0059] FIG. 12 shows the effects of representative SERDs in MCF-7 E3 proliferation assay.
[0060] FIG. 13 shows the effect of SERD 4 on estrogen receptor a (ERa) expression. Western blots showing ER protein expression in MCF-7 cells dramatically downregulated by GDC-810, SERD4, and GW-7604, respectively, in a dose-dependent manner.
[0061] FIG. 14 shows the effect of SERD 9 on estrogen receptor a (ERa) expression. Western blots showing ER protein expression dramatically downregulated by A. Fulvestrant, B. SERD9 in a dose-dependent manner.
[0062 ] FIG. 15 shows the binding of SERD 4 and SERD 9 to estrogen receptor a (ERa) with high affinity.
[0063] FIG. 16 shows the oral bioavailability of SERD 4 and GW7604 in rats after a single dose of 10 mg/kg per os (p.o.) .
[0064] FIG. 17 shows the oral bioavailability of SERD 9 in mice after a single dose of 5 mg/kg p.o.
[0065] FIG. 18 shows the efficacy of SERD 9 in mice bearing breast tumor xenograft when orally administered at two doses, as compared to that of fulvestrant administered by subcutaneous injection.
DETAILED DESCRIPTION
[0066] Before the subject disclosure is further described, it is to be understood that the disclosure is not limited to the particular embodiments of the disclosure described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present disclosure will be established by the appended claims.
[0067] In this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs.
[0068] As used herein, the term "minimize" or "reduce", or derivatives thereof, include a complete or partial inhibition of a specified biological effect (which is apparent from the context in which the terms "minimize" or "reduce" are used).
[0069] The compounds according to the disclosure can be prepared according to the schemes shown in FIGS. 1-10,
[0070] Table 1 below shows the cytotoxicity of the representative SERDs in various breast cancer cell lines.
TABLE 1
[0071] The compounds according to the disclosure are isolated and purified in a manner known per se, e.g. by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as chromatography on a suitable support material. Furthermore, reverse phase preparative HPLC of compounds of the present disclosure which possess a sufficiently basic or acidic functionality, may result in the formation of a salt, such as, in the case of a compound of the present disclosure which is sufficiently basic, a trifluoroacetate or formate salt for example, or, in the case of a compound of the present disclosure which is sufficiently acidic, an ammonium salt for example. Salts of this type can either be transformed into its free base or free acid form, respectively, by various methods known to the person skilled in the art, or be used as salts in subsequent biological assays. Additionally, the drying process during the isolation of compounds of the present disclosure may not fully remove traces of cosolvents, especially such as formic acid or trifluoroacetic acid, to give solvates or inclusion complexes. The person skilled in the art will recognize which solvates or inclusion complexes are acceptable to be used in subsequent biological assays. It is to be understood that the specific form (e.g., salt, free base, solvate, inclusion complex) of a compound of the present disclosure as isolated as described herein is not necessarily the only form in which said compound can be applied to a biological assay in order to quantify the specific biological activity.
[0072] Salts of the compounds of formulas (ΐ) through (X) according to the disclosure can be obtained by dissolving the free compound in a suitable solvent (for example a ketone such as acetone, methylethylketone or methylisobutylketone, an ether such as diethyl ether, tetrahydrofuran or dioxane, a chlorinated hydrocarbon such as methylene chloride or chloroform, or a low molecular weight aliphatic alcohol such as methanol, ethanol or isopropanol) which contains the desired acid or base, or to which the desired acid or base is then added. The acid or base can be employed in salt preparation, depending on whether a mono- or polybasic acid or base is concerned and depending on which salt is desired, in an equimolar quantitative ratio or one differing therefrom. The salts are obtained by filtering,
reprecipitating, precipitating with a non-solvent for the salt or by evaporating the solvent. Salts obtained can be converted into the free compounds which, in turn, can be converted into salts. In this manner, pharmaceutically unacceptable salts, which can be obtained, for example, as process products in the manufacturing on an industrial scale, can be converted into pharmaceutically acceptable salts by processes known to the person skilled in the art.
[0073] All references cited in this specification are herein incorporated by reference as though each reference was specifically and individually indicated to be incorporated by reference. The citation of any reference is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such reference by virtue of prior invention.
[0074] It will be understood that each of the elements described above, or two or more together may also find a useful application in other types of methods differing from the type described above. Without further analysis, the foregoing will so fully reveal the gist of the present disclosure that others can, by applying current knowledge, readily adapt it for various applications without omitting features that, from the standpoint of prior art, fairly constitute essential characteristics of the generic or specific aspects of this disclosure set forth in the appended claims. The foregoing embodiments are presented by way of example only; the scope of the present disclosure is to be limited only by the following claims.
References Cited:
1. Jasani B, Douglas-Jones A, Rhodes A, Wozniak S, Barrett-Lee PJ, Gee J, Nicholson R. Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections. Methods Mol Med. 2006;120:127-46.
2. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009 May 15;169(10):1251-9.
3. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012, 23(6):1378-86.
4. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18: 3758-3767.
5. Nabholtz JM, Bonneterre J, Buzdar A et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003; 39: 1684-1689.
6. Morris C, Wakeling A. Fulvestrant ('Faslodex')— a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer. 2002 Dec;9(4):267-76.
Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM. A good drug made better: the fulvestrant dose-response story. Clin Breast Cancer. 2014, Dec;14(6):381-9.
Robertson JF. Fulvestrant (Faslodex)— how to make a good drug better. Oncologist. 2007 Jul; 12(7):774-84.
Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010, 21 (12):2342-7.
Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, Panasci L, lanuli C, Kahan Z, Fukase K, Lindemann JP, Macpherson MP, Neven P. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010 Sep;123(2):453-61.
NCT01823835, A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer, 2013, http:/ clinicaltrials.gov NCT02248090, AZD9496 First Time in Patients Ascending Dose Study, 2014,
http:/ clinicaltrials.gov
Claims
CLAIMS claimed is:
At least one compound selected from the group consisting of Formula (Γ) through Formula (X), or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
The at least one compound of claim 1 for use in the treatment of a proliferative disease in a mammal in need thereof.
The at least one compound of claim 1 for use in the treatment of a cancer in a mammal in need thereof.
The at least one compound of claim 1 for use in modulating an estrogen receptor in a mammal in need thereof.
A composition comprising the at least one compound of any one of claims 1-4 for use as a medicament.
The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula (Γ):
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, and the R4 substituent point of attachment is on the substituent boron atom of R4, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
7. The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula (II):
wherein
X = O, S, NH, OCH2, SCH2, NHCH2, CH20, CH2S, or CH2NH2
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, and the R4 substituent point of attachment is on the substituent boron atom of R4, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
8. The at least one compound of any one of claims 1-4, wherein said compound is a structure of
Formula (III):
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, and the R4 substituent point of attachment is on the substituent boron atom of R4, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula (IV):
Formula (IV)
wherein
R1 = H, OH, OMe, Me, CI, F, or CF3;
R2 = H, OH, OMe, Me, CI, F, or CF3;
R4 = H, F, or CI;
R5 = H, F, or CI; and
R3 =
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula (V):
Formula (V)
wherein
R1 = H, OH, OMe, Me, CI, F, or CF3;
R2 = H, OH, OMe, Me, CI, F, or CF3;
R4 = H, F, or CI;
R5 = H, F, or CI; and
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
11. The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula (VI) :
wherein
R1 = H, OH, OMe, Me, CI, F, or CF3;
R2 = H, OH, OMe, Me, CI, F, or CF3;
R4 = H, F, or CI;
R5 = H, F, or CI; and
wherein the R3 substituent point of attachment is on the substituent boron atom of R3, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula VII):
wherein the R1 substituent point of attachment is on the substituent boron atom of R1, and the R2 substituent point of attachment is on the substituent boron atom of R2, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula VIII):
wherein the R1 substituent point of attachment is on the substituent boron atom of R1, and the R2 substituent point of attachment is on the substituent boron atom of R2, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula (IX):
wherein the R2 substituent point of attachment is on the substituent boron atom of R2, and the R3 substituent point of attachment is on the substituent boron atom of R3, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
The at least one compound of any one of claims 1-4, wherein said compound is a structure of Formula (X):
wherein the R1 substituent point of attachment is on the substituent boron atom of R1, and the R2 substituent point of attachment is on the substituent boron atom of R2, or a salt thereof, a solvate thereof, or a solvate of a salt thereof.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17793447.8A EP3452486A4 (en) | 2016-05-06 | 2017-05-05 | Selective estrogen receptor down-regulators (serds) |
US16/317,196 US20190233442A1 (en) | 2016-05-06 | 2017-05-05 | Selective estrogen receptor down-regulators (serds) |
CN201780027863.XA CN109415388A (en) | 2016-05-06 | 2017-05-05 | It is adjusted under selective estrogen receptor (SERDS) |
JP2018557799A JP7064772B2 (en) | 2016-05-06 | 2017-05-05 | Selective Estrogen Receptor Down Regulator (SERDS) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662332541P | 2016-05-06 | 2016-05-06 | |
US62/332,541 | 2016-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017192991A1 true WO2017192991A1 (en) | 2017-11-09 |
Family
ID=60203671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/031297 WO2017192991A1 (en) | 2016-05-06 | 2017-05-05 | Selective estrogen receptor down-regulators (serds) |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190233442A1 (en) |
EP (1) | EP3452486A4 (en) |
JP (1) | JP7064772B2 (en) |
CN (1) | CN109415388A (en) |
WO (1) | WO2017192991A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
US10131663B2 (en) | 2016-10-24 | 2018-11-20 | Astrazeneca Ab | Chemical compounds |
US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
US10221173B2 (en) | 2017-01-30 | 2019-03-05 | Astrazeneca Ab | Chemical compounds |
JP2022522670A (en) * | 2019-03-20 | 2022-04-20 | ファーマバイオス エス.ピー.エー. | How to prepare a fulvestrant derivative |
IT202100008066A1 (en) | 2021-03-31 | 2022-10-01 | Ind Chimica Srl | PROCESS FOR THE PREPARATION OF B-[(7α,17β)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTIL)SULFINIL]NONYL]ESTRA-1,3,5( 10)-TRIEN-3-IL]-BORONIC AND PROCESS INTERMEDIATE |
ES2957913R1 (en) * | 2021-05-11 | 2024-05-22 | Ind Chimica Srl | Process for the preparation of acid B-[(7alpha,17beta)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5( 10)-trien-3-yl]-boronic and intermediates of said process |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021213358A1 (en) * | 2020-04-21 | 2021-10-28 | 江苏先声药业有限公司 | Boron-containing compounds and application thereof |
CN113444134A (en) * | 2021-07-22 | 2021-09-28 | 中国药科大学 | Estra-1, 3,5(10) -triene compound, preparation method and medical application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999020646A1 (en) * | 1997-10-23 | 1999-04-29 | American Home Products Corporation | Estra-1,3,5(10)-triene-7alpha-thioethers |
WO2005077968A2 (en) * | 2004-02-13 | 2005-08-25 | Innoventus Project Ab | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity |
WO2010107474A1 (en) | 2009-03-16 | 2010-09-23 | The Research Foundation Of State University Of New York | Antiestrogens for breast cancer therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10112962B2 (en) * | 2014-07-02 | 2018-10-30 | Xavier University | Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group |
-
2017
- 2017-05-05 CN CN201780027863.XA patent/CN109415388A/en active Pending
- 2017-05-05 WO PCT/US2017/031297 patent/WO2017192991A1/en unknown
- 2017-05-05 JP JP2018557799A patent/JP7064772B2/en active Active
- 2017-05-05 EP EP17793447.8A patent/EP3452486A4/en not_active Withdrawn
- 2017-05-05 US US16/317,196 patent/US20190233442A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999020646A1 (en) * | 1997-10-23 | 1999-04-29 | American Home Products Corporation | Estra-1,3,5(10)-triene-7alpha-thioethers |
WO2005077968A2 (en) * | 2004-02-13 | 2005-08-25 | Innoventus Project Ab | 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity |
WO2010107474A1 (en) | 2009-03-16 | 2010-09-23 | The Research Foundation Of State University Of New York | Antiestrogens for breast cancer therapy |
Non-Patent Citations (11)
Title |
---|
BARRIOS CFORBES JFJONAT WCONTE PGRADISHAR WBUZDAR AGELMON KGNANT MBONNETERRE JTOI M: "The sequential use of endocrine treatment for advanced breast cancer: where are we?", ANN ONCOL, vol. 23, no. 6, 2012, pages 1378 - 86 |
DEGORCE ET AL.: "Investigation of ( E )-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators", JOURNAL OF MEDICINAL CHEMISTRY, US, vol. 58, no. 8, 23 April 2015 (2015-04-23), pages 3522 - 3533, XP055240905, DOI: 10.1021/acs.jmedchem.5b00066 |
DEGORCE, S. L. ET AL.: "Investigation of (E)-3-[4-(2-0xo-3-aryl-chromen- 4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down- Regulators", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 8, 2015, pages 3522 - 3533, XP055240905 * |
JASANI BDOUGLAS-JONES ARHODES AWOZNIAK SBARRETT-LEE PJGEE JNICHOLSON R: "Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections", METHODS MOL MED, vol. 120, 2006, pages 127 - 46 |
LIU, J. ET AL.: "Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD", J. MED. CHEM., vol. 59, no. 17, 8 September 2016 (2016-09-08), pages 8134 - 8140, XP055439165 * |
MORRIS CWAKELING A: "Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy", ENDOCR RELAT CANCER, vol. 9, no. 4, December 2002 (2002-12-01), pages 267 - 76 |
NABHOLTZ JMBONNETERRE JBUZDAR A ET AL.: "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results", EUR J CANCER, vol. 39, 2003, pages 1684 - 1689, XP004441204, DOI: 10.1016/S0959-8049(03)00326-5 |
NABHOLTZ JMBUZDAR APOLLAK M ET AL.: "Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial", ARIMIDEX STUDY GROUP. J CLIN ONCOL, vol. 18, 2000, pages 3758 - 3767, XP002236968 |
NAOMI SUZUKI ET AL.: "Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen", INTERNATIONAL JOURNAL OF CANCER, US, vol. 128, no. 4, 15 February 2011 (2011-02-15), pages 974 - 982, XP055632752, DOI: 10.1002/ijc.25659 |
See also references of EP3452486A4 |
SETIAWAN VWMONROE KRWILKENS LRKOLONEL LNPIKE MCHENDERSON BE: "Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study", AM J EPIDEMIOL, vol. 169, no. 10, 15 May 2009 (2009-05-15), pages 1251 - 9 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
US10590130B2 (en) | 2016-10-24 | 2020-03-17 | Astrazeneca Ab | Chemical compounds |
US10131663B2 (en) | 2016-10-24 | 2018-11-20 | Astrazeneca Ab | Chemical compounds |
US10961241B2 (en) | 2016-10-24 | 2021-03-30 | Astrazeneca Ab | Chemical compounds |
US10221173B2 (en) | 2017-01-30 | 2019-03-05 | Astrazeneca Ab | Chemical compounds |
US10590132B2 (en) | 2017-01-30 | 2020-03-17 | Astrazeneca Ab | Selective estrogen receptor down-regulators |
US11046689B2 (en) | 2017-01-30 | 2021-06-29 | Astrazeneca Ab | Selective estrogen receptor down-regulators |
JP2022522670A (en) * | 2019-03-20 | 2022-04-20 | ファーマバイオス エス.ピー.エー. | How to prepare a fulvestrant derivative |
IT202100008066A1 (en) | 2021-03-31 | 2022-10-01 | Ind Chimica Srl | PROCESS FOR THE PREPARATION OF B-[(7α,17β)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTIL)SULFINIL]NONYL]ESTRA-1,3,5( 10)-TRIEN-3-IL]-BORONIC AND PROCESS INTERMEDIATE |
WO2022208157A1 (en) * | 2021-03-31 | 2022-10-06 | Industriale Chimica S.R.L. | Process for the preparation of b-[(7alpha,17beta)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3-yl]-boronic acid and intermediates of said process |
WO2022207607A1 (en) * | 2021-03-31 | 2022-10-06 | Industriale Chimica S.R.L. | PROCESS FOR PREPARING B-[(7α,17β)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID |
FR3121443A1 (en) | 2021-03-31 | 2022-10-07 | Industriale Chimica S.R.L. | Process for the preparation of B-[(7α,17β)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoro-pentyl)sulfinyl]nonyl]estra-1,3,5 acid (10)-trien-3-yl]-boronic and intermediates of said process |
ES2957913R1 (en) * | 2021-05-11 | 2024-05-22 | Ind Chimica Srl | Process for the preparation of acid B-[(7alpha,17beta)-17-hydroxy-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5( 10)-trien-3-yl]-boronic and intermediates of said process |
Also Published As
Publication number | Publication date |
---|---|
EP3452486A1 (en) | 2019-03-13 |
EP3452486A4 (en) | 2020-03-04 |
CN109415388A (en) | 2019-03-01 |
JP7064772B2 (en) | 2022-05-11 |
JP2019514955A (en) | 2019-06-06 |
US20190233442A1 (en) | 2019-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017192991A1 (en) | Selective estrogen receptor down-regulators (serds) | |
JP2016513737A5 (en) | ||
JP6437119B2 (en) | Pharmaceutical combination comprising a selective S1P1 receptor agonist | |
WO2021088938A1 (en) | Tetrahydropyridopyrimidine-based inhibitor, preparation method therefor and use thereof | |
JP2022541749A (en) | Peptide conjugates of cytotoxins as therapeutic agents | |
CN116854745A (en) | Pharmaceutical co-crystal composition and use thereof | |
CA2960910A1 (en) | Nitrogen-containing analogs of salinomycin, synthesis and use against cancer stem cells and malaria | |
WO2016014778A1 (en) | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes | |
JP2018521969A (en) | Pharmaceutical co-crystals and their uses | |
IL268416B1 (en) | Pharmaceutical combinations for treating cancer | |
JP6768716B2 (en) | Carboplatin-based co-crystal pharmaceutical compositions and their uses | |
KR20230117574A (en) | Combinations of METAP2 inhibitors and CDK4/6 inhibitors for cancer treatment | |
EP3849994A1 (en) | Triptolide and prodrugs thereof for use in methods to treat fibrosis, nash, and nafld | |
EP3978473A1 (en) | Compound containing an indoleacetic acid core structure and use thereof | |
JPWO2021007435A5 (en) | ||
KR20090024705A (en) | Ruthenium ii compounds | |
EP3543238B1 (en) | Nucleoside derivatives having anti-viral activity | |
Castro et al. | Cytotoxic activity of synthetic chiral amino acid derivatives | |
US20220041629A1 (en) | Estrogen receptor targeting antagonists | |
EP2730575A1 (en) | Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof | |
US9732091B2 (en) | Tryptophanol-derived oxazoloisoindolinones: small-molecule P53 activators | |
EP3841091A1 (en) | Phenoxy(hetero)aryl ethers of antiproliferative activity | |
JP2017171624A (en) | Anticancer agent | |
FR2986796A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
CN101307041B (en) | Novel taxane halogenation derivates with anti-tumor activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018557799 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17793447 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017793447 Country of ref document: EP Effective date: 20181206 |